{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:28:20Z","timestamp":1648733300581},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"DOI":"10.1007\/s00393-019-00719-9","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T22:27:50Z","timestamp":1572042470000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteoporose: Dauertherapie versus Therapiepause \u2013 Wof\u00fcr gibt es Evidenz?"],"prefix":"10.1007","author":[{"given":"P.","family":"Farahmand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cassens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"719_CR1","unstructured":"S3-Leitlinie Prophylaxe, Diagnostik und Therapie der Osteoporose (2017), AWMF Registernummer 183-001, Dachverband Osteologie e.\u202fV."},{"key":"719_CR2","unstructured":"S3-Leitlinie Antiresorptiva-assoziierte Kiefernekrosen (2017), AWMF Registernummer: 007-091, Schiegnitz E, Al-Nawas B, Hoefert S, Otto S, Pautke C, Ristow O, Voss P, Gr\u00f6tz KA"},{"issue":"7","key":"719_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone\u00a0HG, Wagman\u00a0RB, Brandi\u00a0ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"719_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00223-011-9499-8","volume":"89","author":"R Rizzoli","year":"2011","unstructured":"Rizzoli\u00a0R, Reginster\u00a0JY, Boonen\u00a0S, Br\u00e9art\u00a0G, Diez-Perez\u00a0A, Felsenberg\u00a0D, Kaufman\u00a0JM, Kanis\u00a0JA, Cooper\u00a0C (2011) Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 89:91\u2013104","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"719_CR5","first-page":"324","volume":"60","author":"JP Brown","year":"2014","unstructured":"Brown\u00a0JP, Morin\u00a0S, Leslie\u00a0W et\u00a0al (2014) Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician 60(4):324\u2013333","journal-title":"Can Fam Physician"},{"issue":"22","key":"719_CR6","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker\u00a0M, Guo\u00a0J, Kehoe\u00a0T et\u00a0al (2012) Bisphosphonates for osteoporosis\u2014where do we go from here? N\u00a0Engl J Med 366(22):2048\u20132051","journal-title":"N Engl J Med"},{"key":"719_CR7","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black\u00a0DM, Schwartz\u00a0AV, Ensrud\u00a0KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Ex tension (FLEX): a\u00a0randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"719_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","volume":"32","author":"OH Sorensen","year":"2003","unstructured":"Sorensen\u00a0OH, Crawford\u00a0GM, Mulder\u00a0H et al (2003) Longterm efficacy of risedronate: a\u00a05-year placebo-controlled clinical experience. Bone 32:120\u2013126","journal-title":"Bone"},{"key":"719_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black\u00a0DM, Reid\u00a0I, Boonen\u00a0S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a\u00a0randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J\u00a0Bone Miner Res 27:243\u2013254","journal-title":"J Bone Miner Res"},{"issue":"5","key":"719_CR10","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/jbmr.2442","volume":"30","author":"DM Black","year":"2015","unstructured":"Black\u00a0DM, Reid\u00a0IR, Cauley\u00a0JA et al (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a\u00a0randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J\u00a0Bone Miner Res 30(5):934\u2013944","journal-title":"J Bone Miner Res"},{"issue":"2","key":"719_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2165\/00044011-200525020-00003","volume":"25","author":"KC Lasseter","year":"2005","unstructured":"Lasseter\u00a0KC, Porras\u00a0AG, Denker\u00a0A et al (2005) Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Investig 25(2):107\u2013114","journal-title":"Clin Drug Investig"},{"issue":"5","key":"719_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"GH Nancollas","year":"2006","unstructured":"Nancollas\u00a0GH, Tang\u00a0R, Phipps\u00a0RJ et\u00a0al (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38(5):617\u2013627","journal-title":"Bone"},{"issue":"1","key":"719_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler\u00a0RA, El-Haij Fuleihan\u00a0G, Bauer\u00a0DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a\u00a0task force of the American Society for Bone and Mineral Research. J\u00a0Bone Miner Res 31(1):16\u201335","journal-title":"J Bone Miner Res"},{"issue":"12","key":"719_CR14","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1007\/s00198-017-4215-9","volume":"28","author":"MA Mignot","year":"2017","unstructured":"Mignot\u00a0MA, Taisne\u00a0N, Legroux\u00a0I et\u00a0al (2017) Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporos Int 28(12):3431\u20133438","journal-title":"Osteoporos Int"},{"issue":"4","key":"719_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone\u00a0HG, Bolognese\u00a0MA, Yuen\u00a0CK et\u00a0al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J\u00a0Clin Endocrinol Metab 96(4):972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"719_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1210\/jc.2010-1805","volume":"96","author":"PD Miller","year":"2011","unstructured":"Miller\u00a0PD, Wagman\u00a0RB, Peacock\u00a0M et al (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a\u00a0phase 2 clinical trial. J\u00a0Clin Endocrinol Metab 96(2):394\u2013402","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"719_CR17","first-page":"408","volume":"31","author":"AW Popp","year":"2016","unstructured":"Popp\u00a0AW, Buffat\u00a0H, Senn\u00a0C et al (2016) Rebound-associated bone loss after non-renewal of long-term denosumab treatment offsets 10-year gains at the total hip within 12\u00a0months. J\u00a0Bone Miner Res 31(Suppl 1):408","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"719_CR18","first-page":"384","volume":"31","author":"MB Zanchetta","year":"2016","unstructured":"Zanchetta\u00a0MB, Boailchuk\u00a0J, Massari\u00a0F et\u00a0al (2016) Significant bone loss after stopping denosumab treatment. J\u00a0Bone Miner Res 31(Suppl 1):384","journal-title":"J Bone Miner Res"},{"issue":"5","key":"719_CR19","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung\u00a0MR, Wagman\u00a0RB, Miller\u00a0PD et al (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28(5):1723\u20131732","journal-title":"Osteoporos Int"},{"issue":"11","key":"719_CR20","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/jbmr.448","volume":"26","author":"JP Brown","year":"2011","unstructured":"Brown\u00a0JP, Dempster\u00a0DW, Ding\u00a0B et al (2011) Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. J\u00a0Bone Miner Res 26(11):2737\u20132744","journal-title":"J Bone Miner Res"},{"key":"719_CR21","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier\u00a0B, Gonzalez-Rodriguez\u00a0E, Stoll\u00a0D et al (2016) Severe spontaneous vertebral fractures after Denosumab discontinuation: three case reports. Osteoporos Int 27:1923\u20131925","journal-title":"Osteoporos Int"},{"key":"719_CR22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","volume":"27","author":"AD Anastasilakis","year":"2016","unstructured":"Anastasilakis\u00a0AD, Makras\u00a0P (2016) Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 27:1929\u20131930","journal-title":"Osteoporos Int"},{"issue":"2","key":"719_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings\u00a0SR, Ferrari\u00a0S, Eastell\u00a0R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J\u00a0Bone Miner Res 33(2):190\u2013198","journal-title":"J Bone Miner Res"},{"key":"719_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","volume":"30","author":"SJ Neele","year":"2002","unstructured":"Neele\u00a0SJ, Evertz\u00a0R, De Valk-De Roo\u00a0G et al (2002) Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30:599\u2013603","journal-title":"Bone"},{"issue":"9","key":"719_CR25","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"Lindsay\u00a0R, Scheele\u00a0WH, Neer\u00a0R et\u00a0al (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164(9):2024\u20132030","journal-title":"Arch Intern Med"},{"key":"719_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi\u00a0E, Langdahl\u00a0B, Cohen-Solal\u00a0M et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-00719-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T10:58:13Z","timestamp":1576666693000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-00719-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":26,"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-00719-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"25 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.\u00a0Farahmand ist als Referent f\u00fcr die Firmen AMGEN, Lilly und UCB t\u00e4tig und als Berater f\u00fcr die Firmen AMGEN und UCB. J.\u00a0Cassens ist als Referent f\u00fcr die Firmen AMGEN, Lilly und UCB t\u00e4tig und als Berater f\u00fcr die Firma UCB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}